revenu million
valu usd unless otherwis note
downgrad sector perform in-lin trade
chapter evolv
view downgrad share sector perform
outperform adjust price target view
street overreact recent epacadostat
baricitinib setback share rebound around mid-
valu believ fairli account substanti
jakafi growth opportun out-year patent cliff probability-
adjust pipelin prospect share low
thesi mostli play believ jakafi enabl solid floor
compani impress translat work medicin chemistri
help set compani well long-term nearer term
would expect share trade line visibl
remain posit jakafi growth prospect exist mf/pv
indic believ set solid foundat floor
epidemiolog suggest substanti addit penetr potenti
mf pv limit competit concern continu see jakafi
sale current indic reach long-term alongsid
cash/r engin valu provid floor view
import epacadostat
baricitinib setback out-year jakafi patent cliff start come
onto investor radar oncology/rheumatolog crowd space
robust success jakafi justifi focus
target oncolog io well rhematology/inflamm howev
space increasingli crowd compani gener farther ahead
pursu target like fgfr gitr and/or
deeper pocket might benefit fast follow
believ may abl leverag high-calib translat
scienc medicin chemistri ultim find best-in-class molecul
combo overal may take consider resourc compet
could reduc ultim market share necessit pursuit
nich lower-revenu opportun like multipl shot
goal context strong platform heir appar
epacadostata meaning potenti multibillion-dollar out-year
growth driver gener investor enthusiasm addit near-term
stock upsid hereseem still determin least pend
clariti mf/pv life cycl strategi could come
make model updat better reflect pipelin probabl success
opportun come recent event compani
day increas po jakafi acut gvhd follow
posit data rais averag treatment durat follow
anecdot feedback though still remain continu page
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case assum jakafi sale exceed
 long-term driven continu growth core market
probabl success new indic gvhd
et assum probability-adjust out-
year baricitinib royalti expect topic
ruxolitinib out-year probability-
discount rate termin growth rate
posit phase data jakafi et gvhd extens
jakafi life cycl next-gen combo better-
than-expect success within earlier-stag pipelin would
provid upsid scenario base dcf analysi
would suggest fair valu
erod price power jakafi poor perform
earlier-stag pipelin clinic regulatori setback
jakafi combin would lead downsid case
dcf would suggest fair valu
long-term potenti
jakafi consider
 sale continu beat near-term sale
expect limit downsid risk commerci execut
support strong revenu foundat compani
also believ compani one deepest
cancer-focus pipelin biotech reflect strong
drug discoveri engin busi develop expertis
howev pipelin still matur given competit
space difficult pinpoint asset may
meaning long-term revenu potenti help off-set life
cycl question take togeth believ
long-term growth opportun inher risk
larg pipelin early-stag oncolog asset
posit high opportun jakafi driven growth
exist mf/pv indic long-term opportun
et gvhd strong price power construct partner
good commerci execut deep pipelin cancer-
focus asset potenti drive long-term revenu
risk oncolog rheumatolog space
competit farther behind larger compani
approach make import
compani differenti substanti efficacy/safeti
patent expiri time-frame life-cycl
extens strategi depend early-stag
pim inhibitor may offer accept
efficacy/safeti alon combo jakafi
ii data
fgf-alter tumor snda submiss
jakafi acut gvhd data present
major medic meet submiss
rel modest contributor discret model pipelin program
fgfr potenti contribut topic ruxo ad vitiligo probability-
adjust follow fda reject baricitinib dose label
exclud radiograph benefit humira superior use prior tnf failur
substanti revamp baricitinib model reduc market opportun ra lower
po indic like sle dose shown competit efficaci
seem less like approv out-year probability-adjust sale royalti estim
valuat contribut baricitinib respect
producteventtimelinejakafipresent pivot ph ii acut steroid-refractori file acut gvhd potenti accel approv acut ph iii studi file full approv chronic ph iii studi snda file chronic et trial ruxolitinibpresent ph iib studi atop dermat feedback regard ph iii design ph iii studi ph iii trial biomark data tumor mutat burden rna ph iii treatment-nav acut gvhd combo egfr nsclc data readout ph ii open-label studi low-dos rux combo ph ii clinic trial hidraden ph i/ii dose escal advanc data open label ph i/ii ruxolitinib combin studi mf adv nda submiss on-going fgf-alter studi bladder cholangio ph ii readout bladder cancer w/ continu data fl margin zone mantl cell trial readout monotherapi data open-label ph ii studi ruxolitinib combin cmet readout alk-cmet amplifi doubletscomplet pair biopsi ab initi phase clinic ab initi phase clinic dual inhibitor initi phase clinic data combin checkpoint gitr proof-of-concept data combin checkpoint readout monotherapi msi-high endometri cancer readout monotherapi anal exhibit pipelin
drug/target partner/mechan indicationstatusjakafi nv mf pv gvhd etmarket mf pvolumi ra ad slemarket eu japan pre-registr epacadostatlung cancer epa pembro epa pembro chemo phase iicapmatinib nv cmet nsclcphase brd-i cancerphas carcinomaphas malignanciesphas bladder cancer cholangiocarcinoma mpnsphase sclcphase pim advanc malignanciesphas arg solid tumorsphas gitr solid tumorsphas tumorsphas dual inhibitor cancerpreclinicaltop ruxolitinibatop dermat vitiligo phase combin therapi oncolog monotherapyphas mru cancerpreclinicalpipelin exhibit incom statement
incom statement thousand except share royalties- sale probability-blend iclusig net eu revenu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust pipelin revenu prob-adjust product fair valu acq-rel conting cost incom unreal gain loss long-term debt exchang net pre-tax benefit incom incom per share outstand share outstand exhibit topic ruxolitinib revenu build
dermatitsu popul adult pt mild moder ad patient treat topic probability-weight prob-weight ad patient topic pt pt seek vitiligo patient treat topic probability-weight prob-weight vitiligo patient topic pt topic gross price price per sale topic penetr dermatitsu popul adult pt mild moder ad patient treat topic probability-weight prob-weight ad patient topic pt pt seek vitiligo patient treat topic probability-weight prob-weight vitiligo patient topic eu pt topic price per price eu sale topic ww sale topic exhibit fgfr revenu build
cancer pt bladder stage pt stage mpn pt pt price per price price per prob-weight sale cancer pt bladder stage pt stage mpn pt pt price per price price per prob-weight eu sale prob-weight sale
price target base dcf discount futur cash flow annual
termin growth rate begin jakafi patent expiri price target support
risk rate price target
downsid risk includ greater-than-expect slow jakafi failur extend jakafi life
cycl regulatori setback topic ruxolitinib limit efficaci signal within earlier-
biotechnolog compani focus develop commerci
deep pipelin intern discov small molecul drug candid oncolog
inflammatori indic lead product jakafi ruxolitinib inhibitor market
myelofibrosi mf polycythemia vera pv addit acquisit ariad
eu oper add second approv compound portfolio iclusig cml
incyt wholli own inhibitor epacadostat evalu combin
therapi multipl immune-checkpoint inhibitor solid tumor within inflammatori
diseas space incyt advanc compound baricitinib jak inhibitor out-licens
lilli develop drug rheumatoid arthriti ra indic
baricitinib olumi approv ema februari approv fda
drug also explor indic atop dermat system
lupu erythematosu addit compound wholli own pipelin includ small
molecul inhibitor fgfr brd
